CEL-SCI (CVM) Competitors $0.27 -0.02 (-8.28%) Closing price 04:00 PM EasternExtended Trading$0.26 0.00 (-0.38%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock CVM vs. VXRT, ZNTL, SGMT, GNLX, ZURA, ATOS, SNTI, OPTN, HLVX, and EXOZShould you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include Vaxart (VXRT), Zentalis Pharmaceuticals (ZNTL), Sagimet Biosciences (SGMT), Genelux (GNLX), Zura Bio (ZURA), Atossa Therapeutics (ATOS), Senti Biosciences (SNTI), OptiNose (OPTN), HilleVax (HLVX), and Exozymes (EXOZ). These companies are all part of the "pharmaceutical products" industry. CEL-SCI vs. Vaxart Zentalis Pharmaceuticals Sagimet Biosciences Genelux Zura Bio Atossa Therapeutics Senti Biosciences OptiNose HilleVax Exozymes CEL-SCI (NYSE:CVM) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership. Which has more risk & volatility, CVM or VXRT? CEL-SCI has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Vaxart has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Do institutionals & insiders believe in CVM or VXRT? 12.1% of CEL-SCI shares are owned by institutional investors. Comparatively, 18.0% of Vaxart shares are owned by institutional investors. 14.1% of CEL-SCI shares are owned by company insiders. Comparatively, 2.6% of Vaxart shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is CVM or VXRT more profitable? CEL-SCI has a net margin of 0.00% compared to Vaxart's net margin of -431.61%. Vaxart's return on equity of -110.46% beat CEL-SCI's return on equity.Company Net Margins Return on Equity Return on Assets CEL-SCIN/A -238.05% -104.65% Vaxart -431.61%-110.46%-62.78% Does the MarketBeat Community prefer CVM or VXRT? Vaxart received 311 more outperform votes than CEL-SCI when rated by MarketBeat users. Likewise, 65.61% of users gave Vaxart an outperform vote while only 0.00% of users gave CEL-SCI an outperform vote. CompanyUnderperformOutperformCEL-SCIOutperform VotesNo VotesUnderperform Votes25100.00% VaxartOutperform Votes31165.61% Underperform Votes16334.39% Which has higher earnings and valuation, CVM or VXRT? CEL-SCI has higher earnings, but lower revenue than Vaxart. Vaxart is trading at a lower price-to-earnings ratio than CEL-SCI, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCEL-SCIN/AN/A-$26.92M-$0.48-0.55Vaxart$28.70M3.41-$82.46M-$0.34-1.26 Does the media favor CVM or VXRT? In the previous week, Vaxart had 2 more articles in the media than CEL-SCI. MarketBeat recorded 2 mentions for Vaxart and 0 mentions for CEL-SCI. Vaxart's average media sentiment score of 0.65 beat CEL-SCI's score of 0.00 indicating that Vaxart is being referred to more favorably in the news media. Company Overall Sentiment CEL-SCI Neutral Vaxart Positive Do analysts rate CVM or VXRT? Vaxart has a consensus price target of $3.00, suggesting a potential upside of 599.95%. Given Vaxart's stronger consensus rating and higher probable upside, analysts plainly believe Vaxart is more favorable than CEL-SCI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CEL-SCI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Vaxart 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryVaxart beats CEL-SCI on 13 of the 17 factors compared between the two stocks. Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVM vs. The Competition Export to ExcelMetricCEL-SCIBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$22.38M$2.95B$5.53B$18.96BDividend YieldN/A1.89%5.11%4.01%P/E Ratio-0.5530.0722.5132.87Price / SalesN/A494.82397.6228.03Price / CashN/A168.6838.1817.52Price / Book1.773.176.734.47Net Income-$26.92M-$72.35M$3.22B$1.02B7 Day Performance-8.31%0.95%1.58%0.73%1 Month Performance21.18%8.28%4.05%-2.62%1 Year Performance-81.27%-22.65%15.75%4.59% CEL-SCI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVMCEL-SCIN/A$0.27-8.3%N/A-80.1%$22.38MN/A-0.5543Analyst ForecastVXRTVaxart1.48 of 5 stars$0.45+11.6%$3.00+570.8%-38.5%$102.06M$28.70M-1.09120News CoverageHigh Trading VolumeZNTLZentalis Pharmaceuticals1.9422 of 5 stars$1.42-0.7%$8.24+480.6%-87.2%$101.97M$67.43M-0.57160Upcoming EarningsNews CoverageGap UpSGMTSagimet Biosciences2.8253 of 5 stars$3.31+5.1%$22.40+576.7%-11.5%$101.53M$2M-2.318Positive NewsGNLXGenelux1.6367 of 5 stars$2.90+0.7%$18.25+529.3%-13.5%$100.35M$8,000.00-3.0510Upcoming EarningsNews CoverageZURAZura Bio3.1004 of 5 stars$1.41+2.9%$14.67+940.2%-63.9%$96.41MN/A-2.663Upcoming EarningsShort Interest ↓News CoverageATOSAtossa Therapeutics1.9466 of 5 stars$0.74-1.8%$7.13+859.2%-40.5%$95.95MN/A-3.388Gap UpSNTISenti Biosciences2.8605 of 5 stars$3.64-27.2%$10.00+174.7%-7.8%$94.66M$2.56M-0.234Upcoming EarningsNews CoverageHigh Trading VolumeOPTNOptiNose3.2582 of 5 stars$9.34+0.6%$9.00-3.6%-24.3%$94.59M$78.23M-2.22190Short Interest ↓News CoveragePositive NewsHLVXHilleVax2.775 of 5 stars$1.88+1.6%$3.00+59.6%-85.3%$94.27MN/A-0.6120Upcoming EarningsNews CoveragePositive NewsEXOZExozymesN/A$11.21+4.5%N/AN/A$93.81MN/A0.0029 Related Companies and Tools Related Companies Vaxart Competitors Zentalis Pharmaceuticals Competitors Sagimet Biosciences Competitors Genelux Competitors Zura Bio Competitors Atossa Therapeutics Competitors Senti Biosciences Competitors OptiNose Competitors HilleVax Competitors Exozymes Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CVM) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredWhat if America bought gold like it used to?History Says Gold Wins When This Signal Flashes — and It’s Flashing Now Every time the Buffett Indicator ha...Golden Portfolio | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CVM Stock Free CVM Stock Alerts